Reports Q1 revenue $258K, consensus $299K. “We delivered a strong quarter of Proteus execution, achieving the key development milestones we outlined at our Investor & Analyst Day in November 2025. Most notably, we achieved automated sequencing runs on integrated Proteus instruments bringing together all the core elements of the system planned for the launch configuration spanning instrumentation, KinetIQ(TM) Array, Sequencing chemistry and data analysis, all without user intervention once the run is initiated,” said Jeff Hawkins, President and Chief Executive Officer. “While there is more work ahead, the momentum we are building across all parts of the Proteus development program is encouraging and reinforces our confidence in the roadmap we are executing.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QSI:
- Quantum-Si announces sequencing on Integrated Proteus instruments
- Incyte, BNY Mellon, Quantum-Si, Jabil, Levi Shock
- Quantum-Si announces two customer posters to be presented at AACR meeting
- Quantum-Si announces new manuscript on bioRxiv
- Quantum-Si announces customer samples tested on Proteus prototype system
